Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)

NCT07495579 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

146

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Lenvatinib
DRUG: regorafenib

Sponsor

Asan Medical Center

Collaborators

[object Object]
[object Object]